Search results for "Protectors"

showing 6 items of 6 documents

Radioprotection and Radiomitigation: From the Bench to Clinical Practice.

2020

The development of protective agents against harmful radiations has been a subject of investigation for decades. However, effective (ideal) radioprotectors and radiomitigators remain an unsolved problem. Because ionizing radiation-induced cellular damage is primarily attributed to free radicals, radical scavengers are promising as potential radioprotectors. Early development of such agents focused on thiol synthetic compounds, e.g., amifostine (2-(3-aminopropylamino) ethylsulfanylphosphonic acid), approved as a radioprotector by the Food and Drug Administration (FDA, USA) but for limited clinical indications and not for nonclinical uses. To date, no new chemical entity has been approved by …

0301 basic medicineMedicine (miscellaneous)free radicalsReviewPharmacologyFilgrastimGeneral Biochemistry Genetics and Molecular BiologyIonizing radiation03 medical and health sciences0302 clinical medicineSargramostimNew chemical entitymedicinelcsh:QH301-705.5business.industryradioprotectorsAcute Radiation SyndromeAmifostine030104 developmental biologyantioxidantslcsh:Biology (General)Protective Agents030220 oncology & carcinogenesisradiomitigatorsionizing radiationsbusinessPegfilgrastimmedicine.drugBiomedicines
researchProduct

Controlled delivery of naltrexone by an intraoral device: in vivo study on human subjects.

2013

Naltrexone is widely used in the treatment of opiate addiction but its current peroral administration is characterized by low bioavailability with various side effects. The development of a long-acting transbuccal delivery device (IntelliDrug) for NLX may be useful to improve patient compliance and the therapy effectiveness. The aims of the study are (a) to test basic safety and effectiveness of controlled transbuccal drug delivery on human subjects; (b) to compare NLX bioavailability following transbuccal delivery vs per os conventional delivery; and (c) to test the hypothesis that transbuccal delivery is more efficient than the conventional route. In this randomized cross-over pilot study…

Naltrexone HydrochlorideAdultMaleAdolescentNarcotic AntagonistsPharmaceutical ScienceAddictionBiological AvailabilityPharmacologySmoking cessationNaltrexonelaw.inventionTransbuccal drug deliveryYoung AdultDrug Delivery SystemsRandomized controlled triallawmedicineHumansNaltrexone hydrochlorideNLXCross-Over Studiesbusiness.industryAdministration BuccalTransmucosal deliveryBuccal administrationMiddle AgedCrossover studyNaltrexoneBioavailabilitySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoAnesthesiaDelayed-Action PreparationsDrug deliveryMouth ProtectorsFemalebusinessmedicine.drugInternational journal of pharmaceutics
researchProduct

Predictores de duelo complicado

2008

Pilar.Barreto@uv.es; Patricia.Yi@uv.es OBJETIVO: Estudiar el proceso de evolución en sus primeras etapas tras la pérdida y determinar cuáles son los factores de riesgo y protección previos a la muerte que permiten predecir el surgimiento de posibles complicaciones en los familiares/cuidadores de pacientes oncológicos. MÉTODO: Se evaluaron 236 dolientes cuyos familiares eran pacientes oncológicos atendidos en servicios de cuidados paliativos de Valencia y Madrid y se realizó un seguimiento en 2 momentos temporales: 2 y 6 meses tras la muerte, evaluándose la presencia/ausencia de complicaciones en el proceso de duelo mediante dos criterios diagnósticos (DSM e ICG). RESULTADOS: Se encontró una…

Predicción de duelo complicadoProtectoreslcsh:BF1-990Protectors:PSICOLOGÍA::Asesoramiento y orientación ::Orientación profesional [UNESCO]lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensDuelolcsh:RC254-282lcsh:PsychologyGrief developmentRisk factorsPrediction of complicated bereavementDuelo; Evolución de la pena; Factores de riesgo; Protectores; Predicción de duelo complicadoUNESCO::PSICOLOGÍA::Asesoramiento y orientación ::Orientación profesionalEvolución de la penaBereavementFactores de riesgoPsicooncologia
researchProduct

Effect of combination therapy with hypothermia, magnesium and tirilazad in an experimental model of diffuse cerebral ischemia

2007

Objetivo. Valorar el grado de neuroprotección combinando hipotermia con magnesio y tirilazad en la isquemia cerebral global. La isquemia cerebral es uno de los problemas de mayor interés en la actualidad con unas medidas terapéuticas limitadas. La utilización de la hipotermia, una de las más eficaces, junto con los fármacos neuroprotectores puede ser una alternativa válida. Diseño. Estudio experimental con grupo control y dos niveles de aplicación de medidas terapéuticas. Ámbito. Laboratorio experimental de la Facultad de Medicina. Participantes y método. Veintiocho ratas Wistar sufrieron isquemia cerebral global de 10 minutos de duración mediante la combinación del clampaje carotídeo bilat…

neuroprotectorsbusiness.industryneuroprotectoresmagnesiumCritical Care and Intensive Care Medicinecerebral ischemianeuroprotecciónisquemia cerebralmagnesiotirilazadMedicineneuroprotectionbusinesshipotermiahypothermiaHumanities
researchProduct

Sperm DNA integrity after conventional freezing vs vitrification with and without cryoprotectors

2010

sperm DNA integrity cryoprotectorsSettore BIO/06 - Anatomia Comparata E Citologia
researchProduct

Sperm DNA integrity after conventional freezing vs vitrification with and without cryoprotectors in oligoastenospermic patients

2010

sperm DNA integritycryoprotectorsSettore BIO/06 - Anatomia Comparata E Citologia
researchProduct